Breakthrough in Tissue Engineering: Modeling Sickle Cell Disease with Induced Pluripotent Stem Cells

Research from Boston Children's Hospital has made significant strides in the field of tissue engineering, with a new study modeling sickle cell disease using induced pluripotent stem cells (iPSCs). The team has developed an optimized three-stage erythroid differentiation protocol that generates enucleated, beta-globin-expressing red blood cells from somatically sourced iPSCs. This breakthrough provides a valuable in vitro tool for the study of sickle cell disease and the development of novel treatments.

Key Takeaways:

• Researchers at Boston Children's Hospital have developed an optimized three-stage erythroid differentiation protocol for generating enucleated, beta-globin-expressing red blood cells from somatically sourced iPSCs.
• The protocol uses polyvinyl alcohol (PVA) as a xeno-free formulation, enhancing iRBC production without loss of terminal maturation.
• The study has successfully modeled sickle cell disease in vitro, with iRBCs displaying sickling phenotypes when exposed to hypoxia.
• RNA-sequencing analysis of iPSC-derived SCD reticulocytes revealed dysregulated disease-relevant molecular pathways, suggesting future therapeutic avenues.
• The study has been peer-reviewed and published in Experimental Hematology, with the research demonstrating the potential for patient-specific iRBCs to be used in the study of SCD and the development of novel treatments.
• The research team included Tolulope O. Rosanwo, Ashlee J. Conway, Thomas E. Williamson, and others from Boston Children's Hospital and Harvard Medical School.

Statistics:

• The study used a three-stage erythroid differentiation protocol to generate enucleated, beta-globin-expressing RBCs from somatically sourced iPSCs.
• The protocol showed a significant enhancement of iRBC production when using polyvinyl alcohol (PVA) as a xeno-free formulation.
• The study revealed that SCD iRBCs displayed sickling phenotypes in vitro when exposed to hypoxia.
• RNA-sequencing analysis identified dysregulated disease-relevant molecular pathways in iPSC-derived SCD reticulocytes.

Sources:

• A xeno-free red blood cell differentiation formula models sickle cell disease from somatically sourced patient iPSCs. Experimental Hematology, 2025:105264.
• NewsRx LLC. New Tissue Engineering Findings from Boston Children's Hospital Discussed (A xeno-free red blood cell differentiation formula models sickle cell disease from somatically sourced patient iPSCs). Hematology Week. October 20, 2025; p 453.